ICON PLC
NASDAQ:ICLR

Watchlist Manager
ICON PLC Logo
ICON PLC
NASDAQ:ICLR
Watchlist
Price: 214.25 USD 0.7% Market Closed
Market Cap: 17.7B USD
Have any thoughts about
ICON PLC?
Write Note

ICON PLC
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ICON PLC
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
ICON PLC
NASDAQ:ICLR
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Malin Corporation PLC
ISEQ:MLC
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICON PLC
Glance View

Market Cap
17.7B USD
Industry
Life Sciences Tools & Services

ICON PLC, a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries, has carved a niche for itself in the critical world of clinical research. Founded in 1990 and headquartered in Dublin, Ireland, ICON PLC combines innovative technologies with deep industry expertise to assist clients at every stage of their product development journey. As the demand for faster and more efficient drug development grows, ICON's comprehensive service offerings—including clinical trial management, analytics, and regulatory consulting—position the company as a vital partner for organizations aiming to bring new therapies to market. With a keen focus on improving patient outcomes and ensuring high-quality results, ICON has built a reputation for operational excellence and customer satisfaction. For investors, ICON PLC represents a compelling opportunity in the booming healthcare sector. Its robust financial performance, characterized by consistent revenue growth and healthy profit margins, reflects its capacity to adapt to the evolving landscape of clinical research. Moreover, the company’s strategic acquisitions and investments in cutting-edge technology underscore its commitment to remaining at the forefront of industry advancements. As ICON continues to expand its global footprint and leverage its extensive expertise, it stands to benefit from the rising demand for clinical services and the increasing complexity of modern drug development. With a strong management team and a clear vision for the future, ICON PLC is well-positioned to deliver sustainable value to its shareholders.

ICLR Intrinsic Value
306.4 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

Back to Top